Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LWNO 0901 bevacizumab ± lomustine in recurrent glioblastoma
2009-012186-63Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab and lomustine in glioblastoma (GBM) (2 arms), sponsored by Erasmus MC. Primary endpoint: Progression-free survival at 6 months (6-month PFS). Started Jul 2009; status: active.
02
Drugs
bevacizumablomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2009-012186-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012186-63.